logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Prevention Of Unwanted Pregnancy

    Medications for Prevention Of Unwanted Pregnancy

    FiltersReset Filters
    9 results

    • balcoltra

      (levonorgestrel and ethinyl estradiol)
      Avion Pharmaceuticals
      Usage: Balcoltra is indicated for use in females of reproductive potential to prevent pregnancy.

    • larin 24 fe

      (Norethindrone acetate/Ethinyl Estradiol and Ferrous Fumarate)
      Northstar Rx LLC
      Usage: Larin 24 Fe is indicated for women to prevent pregnancy. Its efficacy in women with a body mass index (BMI) greater than 35 kg/m² has not been evaluated.

    • natazia

      (estradiol valerate and estradiol valerate/dienogest)
      Bayer HealthCare Pharmaceuticals Inc.
      Usage: Natazia® is indicated for preventing pregnancy in women and for treating heavy menstrual bleeding in those without organic pathology who prefer an oral contraceptive. Efficacy in women with a BMI over 30 kg/m² has not been evaluated.

    • nexplanon

      (etonogestrel)
      Organon LLC
      Usage: NEXPLANON® is indicated for use by women to prevent pregnancy.

    • nuvaring

      (etonogestrel and ethinyl estradiol)
      Organon LLC
      Usage: NuvaRing® is indicated for vaginal use in females of reproductive age for the prevention of pregnancy.

    • slynd

      (Drospirenone)
      Exeltis USA, Inc.
      Usage: SLYND is a progestin indicated for use by females of reproductive potential for the prevention of pregnancy.

    • tydemy

      (Drospirenone, Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium)
      Lupin Pharmaceuticals, Inc.
      Usage: Tydemy™ is indicated for females of reproductive potential to prevent pregnancy and for folate supplementation to reduce the risk of neural tube defects in pregnancies conceived while using the product or shortly after discontinuation.

    • xulane

      (norelgestromin and ethinyl estradiol)
      Mylan Pharmaceuticals Inc.
      Usage: Xulane is indicated for preventing pregnancy in women with a body mass index (BMI) < 30 kg/m², where a combined hormonal contraceptive is appropriate. It may be less effective for women weighing 198 lbs. (90 kg) or more and is contraindicated for those with a BMI ≥ 30 kg/m².

    • zafemy

      (Norelgestromin and Ethinyl Estradiol)
      AvKARE
      Usage: ZAFEMY® is indicated for the prevention of pregnancy in women with a BMI < 30 kg/m², suitable for those who can use a combined hormonal contraceptive. It may be less effective in women weighing 198 lbs or more and is contraindicated in women with a BMI ≥ 30 kg/m².